LAS VEGAS, March 6, 2014 /CNW/ - Vansen Pharma Inc. [OTCQB: VNSN] is pleased to announce the appointment of Mr. Ali Moghaddam to its Board of Advisors. Mr. Moghaddam is an accomplished pharmaceutical executive with over 25 years of experience in both Canada and the U.S., having played a transformational role with companies such as Bristol-Myers Squibb Canada, Linson Pharma Inc. (generic business unit of BMS), Allergan Canada, and E-Z-EM Inc. U.S. (now part of Bracco Group). He brings a proven track record of hands-on leadership within the life sciences field, in the areas of Product Life Cycle Management, Sales, Business Development, Marketing, and Finance.
Mr. Moghaddam is currently the Vice President of Sales (Canada) for Actavis Inc., (NYSE: ACT), a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Prior to Actavis, he was the Vice President of Business Development and Commercial Operations, (North America) at Merus Labs International Inc. (NASDAQ:MSLI-TSX:MSL).
Mr. Moghaddam was also a key member of Linson Pharma Inc., Bristol-Myers Squibb's (NYSE:BMY) Pharmacy group, where he orchestrated the launch of generic Pravastatin (Lin Pravastatin). Mr. Moghaddam is a CPA and CMA (Chartered Professional Accountant and Certified Management Account) and holds Bachelors of Commerce and Science degrees from Concordia University in Montreal.
About Vansen Pharma Inc.
Vansen Pharma Inc. is a specialty pharmaceutical company focused on broad therapeutic areas that are anticipated to grow and present an opportunity for major expansion. Vansen will expand its commercial presence by adding complimentary products through in-licensing, co-promotion and acquisitions, resulting in a comprehensive product portfolio. With its US based sales force, Vansen can better serve the increasing healthcare needs of patients and enhance growth. Vansen's current product portfolio of anti-infectives, including Factive®, Spectracef® and Cefditoren Pivoxil®, provides a strong and stable revenue base from which to grow and expand our company. Our experienced management team is aggressively pursuing acquisitions of accretive specialty products, including legacy drugs and cash flow positive healthcare companies. We look forward to executing our growth strategy and creating lasting shareholder value for our investors.
Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of Section 21E (i) (1) of the United States Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Vansen's actual results to be materially different from any future results expressed or implied by these statements. Such statements include but are not limited to, that Vansen will expand its commercial presence by adding complimentary products through in-licensing, co-promotion and acquisitions, resulting in a comprehensive product portfolio, or that Vansen's current product portfolio will provide a strong and stable revenue base from which to grow and expand the company. Such factors include the following: general economic and business conditions, changes in demand for Vansen's products, changes in competition, the ability of Vansen to integrate acquisitions or complete future acquisitions, interest rate fluctuations, currency exchange rate fluctuations, dependence upon and availability of qualified personnel and changes in government regulation. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Vansen that Vansen's plans and objectives will be achieved. These forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.
SOURCE: Vansen Pharma Inc.
For further information:
Vansen Pharma Inc.
#1115-754, 6955 N Durango Drive
Las Vegas, NV 89149 USA
Tel: (702) 843-0456